The DDL Conference, taking place in Edinburgh, Scotland, attracts over 1,000 global experts annually, including scientists, clinicians, and industry leaders. Belhaven Biopharma will present these ...
A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...